Literature DB >> 15739058

[Reoperation for thyroid cancer].

H Vogelsang1, T Brückner, K Scheidhauer, M Schwaiger, J R Siewert.   

Abstract

Reoperation for thyroid cancer needs to consider patient-, tumor- and therapy-related aspects as well as present diagnostic results. Reoperation because of thyroid remnants, persistence of the primary tumor and lymph node metastasis (completion surgery) has to be distinguished from reoperation due to locoregional recurrence (primary tumor, lymph nodes). The primary surgical strategy should avoid the need for reoperation. The extent of reoperation is related to the extent of primary surgery, stage, and distant metastasis. The timing and indication of reoperation for differentiated thyroid carcinoma in an interdisciplinary multimodal treatment setting depends on diagnostic radioiodine scans and radioiodine therapy. Long-term, recurrence-free survival is achieved by sufficiently radical surgery with acceptable morbidity, including all additive or adjuvant treatment options.

Entities:  

Mesh:

Year:  2005        PMID: 15739058     DOI: 10.1007/s00104-005-1006-1

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  34 in total

1.  AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology.

Authors:  R H Cobin; H Gharib; D A Bergman; O H Clark; D S Cooper; G H Daniels; R A Dickey; D S Duick; J R Garber; I D Hay; J S Kukora; H M Lando; A B Schorr; M A Zeiger
Journal:  Endocr Pract       Date:  2001 May-Jun       Impact factor: 3.443

2.  18F-labeled fluorodeoxyglucose positron emission tomography-guided surgery for recurrent colorectal cancer: a feasibility study.

Authors:  E E Zervos; D C Desai; L R DePalatis; D Soble; E W Martin
Journal:  J Surg Res       Date:  2001-05-01       Impact factor: 2.192

3.  Surgical reintervention for differentiated thyroid cancer.

Authors:  P E Goretzki; D Simon; A Frilling; J Witte; C Reiners; M Grussendorf; F A Horster; H D Röher
Journal:  Br J Surg       Date:  1993-08       Impact factor: 6.939

Review 4.  Management of thyroid cancer.

Authors:  Louiza Vini; Clive Harmer
Journal:  Lancet Oncol       Date:  2002-07       Impact factor: 41.316

5.  Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma.

Authors:  M Schlumberger; M Tubiana; F De Vathaire; C Hill; P Gardet; J P Travagli; P Fragu; J Lumbroso; B Caillou; C Parmentier
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

6.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

Review 7.  Thyroid cancer nodal metastases: biologic significance and therapeutic considerations.

Authors:  S K Grebe; I D Hay
Journal:  Surg Oncol Clin N Am       Date:  1996-01       Impact factor: 3.495

8.  Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy.

Authors:  J H Kim; R D Leeper
Journal:  Cancer       Date:  1987-11-15       Impact factor: 6.860

9.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

10.  Principals of limited or radical surgery for differentiated thyroid cancer.

Authors:  H D Roeher; D Simon; J Witte; P E Goretzki
Journal:  Thyroidology       Date:  1993-12
View more
  2 in total

1.  Morbidity and long-term survival in patients with cervical re-exploration for papillary thyroid carcinoma.

Authors:  Nenia Baerbock; Anke Mittelstädt; Joachim Jähne
Journal:  Innov Surg Sci       Date:  2019-03-27

2.  [Lymph node dissection in papillary and follicular thyroid cancer].

Authors:  C Vorländer; R H Lienenlüke; R A Wahl
Journal:  Chirurg       Date:  2008-06       Impact factor: 0.920

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.